{
    "clinical_study": {
        "@rank": "134474", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (ketoprofen)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive ketoprofen PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity."
            }, 
            {
                "arm_group_label": "Arm II (placebo)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients receive placebo PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized clinical trial studies ketoprofen in preventing lymphedema in patients at\n      high risk after undergoing axillary lymph node dissection. Ketoprofen may prevent lymphedema\n      in patients undergoing axillary lymph node dissection."
        }, 
        "brief_title": "Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema in Patients At High Risk After Undergoing Axillary Lymph Node Dissection", 
        "condition": [
            "Lymphedema", 
            "Unspecified Adult Solid Tumor, Protocol Specific"
        ], 
        "condition_browse": {
            "mesh_term": "Lymphedema"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To evaluate the efficacy of ketoprofen in improving chronic lymphedema while further\n      elucidating the role of inflammatory and lymph angiogenic processes in the pathogenesis of\n      this disease.\n\n      OUTLINE: Patients are randomized to 1 of 2 treatment arms.\n\n      ARM I: Patients receive ketoprofen orally (PO) thrice daily (TID) for up to 1 year in the\n      absence of disease progression or unacceptable toxicity.\n\n      ARM II: Patients receive placebo PO TID for up to 1 year in the absence of disease\n      progression or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up for 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Axillary lymph node dissection within the preceding 12 months\n\n        Exclusion Criteria:\n\n          -  Patients with active cancer\n\n          -  Patients with lymphedema\n\n          -  Infection or bleeding tendency\n\n          -  Patients with medical contraindications to nonsteroidal anti-inflammatory drugs\n             (NSAIDs), including history of allergies, know gastrointestinal intolerance\n\n          -  Other serious systemic illness (e.g., renal failure, hepatic dysfunction, congestive\n             heart failure, neurological or psychological impairment) that would impair the\n             patients' ability to participate\n\n          -  Persons not competent to consent\n\n          -  Patients on aspirin therapy\n\n          -  Minors (< 18 years of age)\n\n          -  Pregnant and/or lactating women\n\n          -  Males"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01893879", 
            "org_study_id": "BRSNSTU0028", 
            "secondary_id": "NCI-2012-02290"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm II (placebo)", 
                "description": "Given PO", 
                "intervention_name": "placebo", 
                "intervention_type": "Other", 
                "other_name": "PLCB"
            }, 
            {
                "arm_group_label": "Arm I (ketoprofen)", 
                "description": "Given PO", 
                "intervention_name": "ketoprofen", 
                "intervention_type": "Drug", 
                "other_name": [
                    "capisten", 
                    "Orudis", 
                    "Oruvail"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm I (ketoprofen)", 
                    "Arm II (placebo)"
                ], 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ketoprofen"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 3, 2014", 
        "location": {
            "contact": {
                "email": "srockson@cvmed.stanford.edu", 
                "last_name": "Stanley Rockson", 
                "phone": "650-498-7061"
            }, 
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford University Hospitals and Clinics"
            }, 
            "investigator": {
                "last_name": "Stanley Rockson", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema in High Risk Patients", 
        "overall_official": {
            "affiliation": "Stanford University Hospitals and Clinics", 
            "last_name": "Stanley Rockson", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of lymphedema and/or severity of lymphedema", 
            "safety_issue": "No", 
            "time_frame": "Up to 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01893879"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Stanford University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}